Cartesian Therapeutics Inc(RNAC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:54 PM ET (Korea 10/31 05:54)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -5.94 | Insider Own | 54.73% | Shs Outstand | 30.0M | Perf Week | 5.02% |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | -38.46% | Insider Trans | - | Shs Float | 13.7M | Perf Month | -10.11% |
| Enterprise Value | 0.11B | PEG | - | EPS next Q | -1.01 | Inst Own | 28.85% | Short Float | 13.69% | Perf Quarter | -17.53% |
| Income | -0.15B | P/S | 132.67 | EPS this Y | 40.17% | Inst Trans | 20.88% | Short Ratio | 14.32 | Perf Half Y | 4.34% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 5.77% | ROA | -43.52% | Short Interest | 1.88M | Perf YTD | -9.99% |
| Book/sh | -4.17 | P/C | 1.33 | EPS past 3/5Y | - 24.48% | ROE | - | 52W High | -41% ($11.00) | Perf Year | -19.98% |
| Cash/sh | 4.88 | P/FCF | - | Sales past 3/5Y | -70.66% -29.96% | ROIC | - | 52W Low | 15.89% ($5.60) | Perf 3Y | -82.83% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 88.72% | Gross Margin | -76.57% | Volatility(W/M) | 5.96% 5.93% | Perf 5Y | -93.97% |
| Dividend TTM | - | EV/Sales | 76.08 | Sales Y/Y TTM | - | Oper. Margin | -6679.69% | ATR (14) | 0.4 | Perf 10Y | -98.7% |
| Dividend Ex-Date | - | Quick Ratio | 7.48 | EPS Q/Q | -23.51% | Profit Margin | -10422.48% | RSI (14) | 41.88 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.48 | Sales Q/Q | -100% | SMA20 | -1.18% ($6.57) | Beta | 0.73 | Target Price | $33.67 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -16.1% ($7.74) | Rel Volume | 0.6 | Prev Close | $6.75 |
| Employees | 75 | LT Debt/Eq | - | EPS/Sales Surpr. | 152.4% -100% | SMA200 | -15.14% ($7.65) | Avg Volume(3M) | 0.13M | Price | $6.49 |
| IPO | 2016/6/22 | Option/Short | Yes/Yes | Trades | 1467 | Volume | 78,469 | Change | -3.85% |
🧬 This is a clinical-stage biotech company developing mRNA cell therapies aimed at autoimmune diseases. Its lead candidate, Descartes-08, is an mRNA-based chimeric antigen receptor T-cell (CAR-T) therapy that targets a specific antigen, with clinical trials primarily focused on generalized myasthenia gravis. A key differentiator is that it can be administered on an outpatient basis without requiring lymphodepleting chemotherapy.
Over the past 1 year, on the lower side
41% below its 1-year high.
Traded less than usual. That is 60% of its average volume.
RNAC has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +40.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $13,267. Peers typically go for $1,089. It is about in line with its own 1-year average.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #299 of 595 in the industry
Based on market cap of $196M.
ARTV#298 Artiva Biotherapeutics Inc $205M PER - RNAC#299 Cartesian Therapeutics Inc $196M PER - 
PRQR#300 ProQR Therapeutics N.V $196M PER - 
DTIL#301 Precision Biosciences Inc $195M PER - 
ACOG#302 Alpha Cognition Inc $190M PER - 
FAQ
What kind of company is RNAC?
RNAC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RNAC?
The market cap of RNAC is approximately $196M, ranking 4,016 within its sector.
What is the 52-week high and low for RNAC?
RNAC has recorded a 52-week high of $11.00 and a low of $5.60.
